Pragma&c Clinical Trials
|
|
- Dominick Moore
- 5 years ago
- Views:
Transcription
1 Pragma&c Clinical Trials Susanne May, PhD Associate Professor Department of Biosta&s&cs, School of Public Health, University of Washington
2 Preliminaries PLEASE ask ques&ons at any &me REALLY good clinical trials web site: < Sept 19, 2014 Pragma&c Trials - Instructor: SMay 2
3 Outline Background Pragma&c clinical trials Example 1 efficacy vs effec&veness Example 2 cross- over Summary Sept 19, 2014 Pragma&c Trials - Instructor: SMay 3
4 Start at the end Where do we want to be? Find a new treatment that improves health of individuals Find a new treatment that improves health of the popula&on Treatments administered to a community Treatments tested on a popula&on Sept 19, 2014 Pragma&c Trials - Instructor: SMay 4
5 Start at the end Where do we want to be? Find a new treatment that improves health of individuals Find a new treatment that improves health of the popula&on Treatments administered to a community Treatments tested on a popula&on Write the manuscript? Sept 19, 2014 Pragma&c Trials - Instructor: SMay 5
6 Clinical Trials in Context Observa&onal epidemiology of disease, risk Preclinical experiments Laboratory, animal studies of mechanisms, toxicology Clinical trials Safety for further inves&ga&ons / dose Safety of therapy Measures of efficacy Confirma&on of efficacy / effec&veness Synthesis and quan&fica&on of evidence Adop&on of new treatment indica&on Sept 19, 2014 Pragma&c Trials - Instructor: SMay 6
7 Treatment Indica&on Disease Puta&ve cause vs signs / symptoms May involve method of diagnosis, response to therapies Popula&on Restrict by risk of AEs or actual prior experience Treatment or treatment strategy Formula&on, administra&on, dose, frequency, dura&on, ancillary therapies Outcome Clinical vs surrogate; &meframe; measurement Sept 19, 2014 Pragma&c Trials - Instructor: SMay 7
8 Level of Evidence U.S. Preven&ve Services Task Force Level I: At least one properly designed RCT Level II: II- 1: Well- designed, nonrandomized CT II- 2: Well- designed, mul¢er cohort/case- control II- 3: Mul&ple &me series with/without interven&on; Drama&c results from uncontrolled trial Level III: Opinions of respected authori&es = Eminence based (not their wording!) Sept 19, 2014 Pragma&c Trials - Instructor: SMay 8
9 Anecdotal observa&ons Case report Case series Hypothesis genera&on Types of Studies That's not an experiment you have there, that's an experience. Sir Ronald A. Fisher ( ) The plural of anecdote is not data. Roger Brinner Sept 19, 2014 Pragma&c Trials - Instructor: SMay 9
10 Types of Studies Designed observa&onal study: Case - control Sample diseased and nondiseased Examine rates of exposures Efficient for rare diseases Can look at mul&ple risk factors Limita&on: Cannot infer cause and effect Correla&ons with other factors Protopathic associa&ons Sept 19, 2014 Pragma&c Trials - Instructor: SMay 10
11 Types of Studies Designed observa&onal study: Cohort study Sample exposed and nonexposed Examine rates of disease Efficient for common diseases Can look at mul&ple diseases Can iden&fy retrospec&ve cohort Limita&on: Cannot infer cause and effect Correla&ons with other factors Protopathic associa&ons Sept 19, 2014 Pragma&c Trials - Instructor: SMay 11
12 Types of Studies Designed interven&onal study: Clinical trial Assign subjects to treatments Examine outcomes Can look at mul&ple diseases Can infer cause and effect Sept 19, 2014 Pragma&c Trials - Instructor: SMay 12
13 Clinical Trials Experimenta&on in human volunteers Inves&gates a new treatment/preven&ve agent Safety: Do adverse effects outweigh poten&al benefit? Efficacy: Does treatment beneficially alter the disease process Effec&veness: Would adop&on of the treatment improve morbidity / mortality in the popula&on? Sept 19, 2014 Pragma&c Trials - Instructor: SMay 13
14 Efficacy: A Moving Target Defini&on of efficacy can vary widely according to choice of endpoint and magnitude of importance Basic science Does treatment have any effect on the pathway Clinical science Does treatment have a sufficiently large effect on a clinically relevant endpoint in some subpopula&on of the target popula&on Sept 19, 2014 Pragma&c Trials - Instructor: SMay 14
15 Effec&veness: A Moving Target A treatment is effec&ve if its introduc&on improves health in the popula&on Considers the net effect of safety and efficacy in the popula&on as a whole Takes into account such issues as Noncompliance Off- label use Sept 19, 2014 Pragma&c Trials - Instructor: SMay 15
16 Effec&veness vs Efficacy A treatment can be both efficacious and ineffec&ve depending on such factors as Target popula&on Restricted eligibility due to toxicity, compliance Interven&on Training, quality control, compliance Comparison treatment No treatment, ac&ve treatment, ancillary treatments Measurement of outcome(s) Clinical disease vs subclinical markers Summary measure of outcome distribu&on Effects on mean, median, outliers Sept 19, 2014 Pragma&c Trials - Instructor: SMay 16
17 Effec&veness vs Efficacy May differ with respect to Certainty of diagnosed disease Subgroups with more (less) severe disease Tolerance of treatment Willingness to comply with treatment Ancillary treatments Different risk factors Sept 19, 2014 Pragma&c Trials - Instructor: SMay 17
18 Outline Background Pragma&c clinical trials Example 1 efficacy vs effec&veness Example 2 cross- over Summary Sept 19, 2014 Pragma&c Trials - Instructor: SMay 18
19 Pragma&c vs Explanatory Thorpe et al define a pragma&c study as follows:... authors coined the term pragma&c to describe trials that help users choose between op&ons for care And explanatory to describe trials that test causal research hypotheses (i.e., that a given interven&on causes a par&cular benefit). Sept 19, 2014 Pragma&c Trials - Instructor: SMay 19
20 Pragma&c vs Explanatory Pragma&c trials are primarily designed to determine the effects of an interven&on under the usual condi&ons in which it will be applied whereas explanatory trials are primarily designed to determine the effects of an interven&on under ideal circumstances. Sept 19, 2014 Pragma&c Trials - Instructor: SMay 20
21 Consort Extension: Pragma&c From Table 1: Key differences between trials with explanatory and pragma&c aptudes, adapted from a table presented at the 2008 Society for Clinical Trials mee&ng by Marion Campbell, University of Aberdeen Sept 19, 2014 Pragma&c Trials - Instructor: SMay 21
22 Comparison Efficacy can the interven&on work? Sepng Well resourced, ideal sepng Par&cipants Highly selected. Poorly adherent par&cipants and those with condi&ons which might dilute the effect are oqen excluded Effec&veness does the interven&on work when used in normal prac&ce? Sepng Normal prac&ce Par&cipants Lirle or no selec&on beyond the clinical indica&on of interest Sept 19, 2014 Pragma&c Trials - Instructor: SMay 22
23 Comparison Efficacy Interven&on Strictly enforced and adherence is monitored closely Outcomes Oqen short term surrogates or process measures Effec&veness Interven&on Applied flexibly as it would be in normal prac&ce Outcomes Directly relevant to par&cipants, funders, communi&es, and healthcare prac&&oner Sept 19, 2014 Pragma&c Trials - Instructor: SMay 23
24 Comparison Efficacy Relevance to prac&ce Indirect lirle effort made to match design of trial to decision making needs of those in usual sepng in which interven&on will be implemented Effec&veness Relevance to prac&ce Direct trial is designed to meet needs of those making decisions about treatment op&ons in sepng in which interven&on will be implemented Sept 19, 2014 Pragma&c Trials - Instructor: SMay 24
25 Outline Background Pragma&c clinical trials Example 1 efficacy vs effec&veness Example 2 cross- over Summary Sept 19, 2014 Pragma&c Trials - Instructor: SMay 25
26 Example 1 ROC PRIMED Lancet Sept 19, 2014 Pragma&c Trials - Instructor: SMay 26
27 Example Example Design/Sta&s&cs Double- blind placebo controlled cross- over trial Completed Needed help with sta&s&cal analysis and write- up Sept 19, 2014 Pragma&c Trials - Instructor: SMay 27
28 Outline Background Pragma&c clinical trials Example 1 efficacy vs effec&veness Example 2 cross- over Summary Sept 19, 2014 Pragma&c Trials - Instructor: SMay 28
29 Example: Cross- over trial Typical design for two treatments A B Wash-out period B A Outcome before treatment Outcome after end of treatment Outcome before treatment Outcome after end of treatment Sept 19, 2014 Pragma&c Trials - Instructor: SMay 29
30 Example: Cross- over trial Design for this study Primary outcome Hemoglobin level Secondary outcome Frequency and intensity of nose bleeds Time points of evalua&on Before treatment ini&a&on 3 months 6 months Sept 19, 2014 Pragma&c Trials - Instructor: SMay 30
31 Example: Cross- over trial Design for this study A B No Wash-out period B A Outcome before treatment Outcome Outcome after end of = = before treatment treatment Outcome after end of treatment Sept 19, 2014 Pragma&c Trials - Instructor: SMay 31
32 Example: Cross- over trial Poten&al issues Last observa&on from first phase = first observa&ons last phase No wash- out period jus&fiable? Sept 19, 2014 Pragma&c Trials - Instructor: SMay 32
33 Example: Cross- over trial What if there is an effect under A? Increase by 5. Calcula&ons Change under A AB sequence hba [t=0] hba [t=3] BA sequence hba [t=3] hba [t=6] Sept 19, 2014 Pragma&c Trials - Instructor: SMay 33
34 Example: Cross- over trial What if there is an effect under A? Increase by 5. Calcula&ons Change under A Change under B AB sequence hba [t=0] hba [t=3] ( hbb [t=3] hbb [t=6] ) BA sequence hba [t=3] hba [t=6] ( hbb [t=0] hbb [t=3] ) Under this calcula&on they should be the same!!! Sept 19, 2014 Pragma&c Trials - Instructor: SMay 34
35 What if there is an effect under A? Increase by 5. Calcula&ons Example: Cross- over trial Change under A Change under B AB sequence hba [t=0] hba [t=3] ( hbb [t=3] hbb [t=6] ) 9 14 ( 14 9 ) = 10 increase by 5 return to BL Sept 19, 2014 Pragma&c Trials - Instructor: SMay 35
36 Example: Cross- over trial What if there is an effect under A? Increase by 5. Calcula&ons Change under A Change under B AB sequence hba [t=0] hba [t=3] ( hbb [t=3] hbb [t=6] ) 9 14 ( 14 9 ) = 10 BA sequence hba [t=3] hba [t=6] ( hbb [t=0] hbb [t=3] ) 9 14 ( 9 9 ) = 5 increase by 5 return to/stay at BL Under this calcula&on they should be the same!!! Sept 19, 2014 Pragma&c Trials - Instructor: SMay 36
37 Example: Cross- over trial Absence of carry- over effect violated Basic premise underlying the design Misunderstanding wash- out period Wash- out of drug in the system Sustained effect on hemoglobin Sept 19, 2014 Pragma&c Trials - Instructor: SMay 37
38 Example: Cross- over trial N = 106 pa&ents interested and contacted N = 34 examined N = 22 started drug intake N = 2 non- compliant 9 Female, 11 Male 52 mean age (range 34 72) Sept 19, 2014 Pragma&c Trials - Instructor: SMay 38
39 Example: Cross- over trial Borom line? Sta&s&cian NEEDS to understand concepts of the applica&on Inves&gator NEEDS to understand concepts of the sta&s&cal analysis Sept 19, 2014 Pragma&c Trials - Instructor: SMay 39
40 Outline Background Pragma&c clinical trials Example 1 efficacy vs effec&veness Example 2 cross- over Summary Sept 19, 2014 Pragma&c Trials - Instructor: SMay 40
41 Summary Interplay science ó sta&s&cs Efficacy / explanatory Effec&veness / Pragma&c Start at the end. Sept 19, 2014 Pragma&c Trials - Instructor: SMay 41
42
Welcome! Pragmatic Clinical Studies. David Hickam, MD, MPH Program Director Clinical Effectiveness Research. David Hickam, MD, MPH
Pragmatic Clinical Studies David Hickam, MD, MPH Program Director Clinical Effec2veness Research June 23, 2015 Welcome! David Hickam, MD, MPH Program Director Clinical Effectiveness Research 2 In this
More informationLearning Objec1ves. Study Design Considera1ons in Clinical Pharmacy
9/28/15 Study Design Considera1ons in Clinical Pharmacy Ludmila Bakhireva, MD, PhD, MPH Pree Sarangarm, PharmD, BCPS Learning Objec1ves Describe the features, advantages and disadvantages of the observa1onal
More informationLearning Objec1ves. Study Design Strategies. Cohort Studies 9/28/15
9/28/15 Learning Objec1ves Describe the features, advantages and disadvantages of the observa1onal study designs Explain why the overall study design is important when evalua1ng studies & applying their
More information3/31/2015. Designing Clinical Research Studies: So You Want to Be an
Designing Clinical Research Studies: So You Want to Be an Inves@gator Andrea Bonny, MD Ellen Lançon Connor, MD On behalf Of The NASPAG Research CommiPee Objec@ves Learn to design a clinical research project
More informationDesign, Conduct and Analysis of Pragma?c Clinical Trials in Pallia?ve Care Research
Design, Conduct and Analysis of Pragma?c Clinical Trials in Pallia?ve Care Research Sco$ D. Halpern, M.D., Ph.D. Associate Professor of Medicine, Epidemiology, and Medical Ethics & Health Policy Director,
More informationUnderstanding. Design & Sta/s/cs. in Clinical Trials
Understanding Design & Sta/s/cs in Clinical Trials 1 Why bother? 2 Experience- Based Medicine? Benjamin Rush Father of American Psychiatry 3 Experience- Based Medicine? Supported blood- lejng as treatment
More informationSta$s$cs is Easy. Dennis Shasha From a book co- wri7en with Manda Wilson
Sta$s$cs is Easy Dennis Shasha From a book co- wri7en with Manda Wilson Is the Coin Fair? You toss a coin 17 $mes and it comes up heads 15 out of 17 $mes. How likely is it that coin is fair? Could look
More informationStudy Designs in HIV Research
Study Designs in HIV Research Colette Smith (based on slides from Fiona Lampe) UK CAB meeting Thursday 17th August 2017 Main types of research studies Cross-sectional Observational Ecological Cohort Case-control
More informationBiosta's'cs Board Review. Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016
Biosta's'cs Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016 Review key biosta's'cs concepts Understand 2 X 2 tables Objec'ves By the end of this
More informationCasual Methods in the Service of Good Epidemiological Practice: A Roadmap
University of California, Berkeley From the SelectedWorks of Maya Petersen 2013 Casual Methods in the Service of Good Epidemiological Practice: A Roadmap Maya Petersen, University of California, Berkeley
More informationCommon Data Elements: Making the Mass of NIH Measures More Useful
Common Data Elements WG Common Data Elements: Making the Mass of NIH Measures More Useful Jerry Sheehan Assistant Director for Policy Development Na?onal Library of Medicine Gene/c Alliance Webinar Series
More informationPublic Health / Public Works Introduc6on, reitera6on + Lessons 1-2. Pioneer Winter IDH 3034, IDH 4007
Public Health / Public Works Introduc6on, reitera6on + Lessons 1-2 Pioneer Winter IDH 3034, IDH 4007 What s the purpose of this class? Learning Objec6ves Understand the principles of public health, epidemiology,
More informationClinical Research Project Design and Guidelines: Choosing a Research Ques8on
Clinical Research Project Design and Guidelines: Choosing a Research Ques8on Odunayo M. Oluwatosin, FMCS (Nig) Department of Plas?c Surgery University College Hospital Ibadan 1 Learning outcome: by the
More informationBlue Cross Blue Shield of Michigan Building a Statewide PCMH Program: Design, Evalua>on Methods, and Results
Blue Cross Blue Shield of Michigan Building a Statewide PCMH Program: Design, Evalua>on Methods, and Results Margaret Mason, MHSA Michael Paus6an, PhD, MS Amanda Markovitz, MPH 1 Overview of BCBSM Serving
More informationMAKING PRAGMATIC TRIALS WORK
MAKING PRAGMATIC TRIALS WORK iden6fica6on of opera6onal challenges & development of a decision support tool for pragma6c trial design WP3 Iris Goetz, Mira Zuidgeest November 24, 2016 Pragma6c trials on
More informationLAI: Linee guida ed esperienze internazionali
LAI: Linee guida ed esperienze internazionali LAI: Guidelines and interna5onal experience PM Llorca CHU Clermont-Ferrand EA 7280 Université Clermont Auvergne Disclosures Advisory board: Allergan, Jansen,
More informationDiscovering And Developing Drugs To Treat Addic4ons: From Models To Medicines
Discovering And Developing Drugs To Treat Addic4ons: From Models To Medicines Phil Skolnick, Ph.D., D.Sc. (hon.) Director, Division of Pharmacotherapies and Medical Consequences of Drug Abuse The Gains
More informationEconomic outcomes: Method for implementa5on
Economic outcomes: Method for implementa5on Philippe Beutels Centre for Health Economics Research & Modelling Infec
More informationFor Objec*ve Causal Inference, Design Trumps Analysis. Donald B. Rubin Department of Sta*s*cs Harvard University 16 March 2012
For Objec*ve Causal Inference, Design Trumps Analysis Donald B. Rubin Department of Sta*s*cs Harvard University 16 March 2012 1 Prologue to Objec*ve Causal Inference in Observa*onal Studies My Introduc*on
More informationDemonstra*ng Respect & Enhancing Trust: Mastering the Informed Consent Process. Informed consent. Objectives. Why obtain consent for research?
Demonstra*ng Respect & Enhancing Trust: Mastering the Informed Consent Process Michael Green, MD, MPH Professor of Pediatrics, Surgery & Clinical and Transla*onal Science Clinical Transla*onal Science
More informationDevelopment and Applica0on of Real- Time Clinical Predic0ve Models
Development and Applica0on of Real- Time Clinical Predic0ve Models Ruben Amarasingham, MD, MBA Associate Professor, UT Southwestern Medical Center AHRQ- funded R24 UT Southwestern Center for Pa?ent- Centered
More informationSta$s$cs, the Law, and the Future of Personalized Medicine. (What happened over spring break)
Sta$s$cs, the Law, and the Future of Personalized Medicine (What happened over spring break) Mayo v. Prometheus Prometheus Laboratories, Inc. developed a diagnos$c test for direc$ng treatment of immune-
More informationHealth Informa.cs. Lecture 9. Samantha Kleinberg
Health Informa.cs Lecture 9 Samantha Kleinberg samantha.kleinberg@stevens.edu Next week: journal club For all papers: read, and prepare to comment on For your paper: Read the ar.cle (+ other references
More informationA large database study in the general population in England
Time-dependent markers of comorbidity severity and change are associated with increased risk of mortality in heart failure: A large database study in the general population in England Claire A. Rushton,
More informationIndependence Well- being and Choice 2005, Our health, our care, our say 2006, Strong and Prosperous 2006
Medicines Op+misa+on Outcome focused approach to safe and effec+ve use of medicines that takes into account the pa+ent s values, percep+on and experience of taking their medicines Important Outcomes for
More informationPropensity Score. Overview:
Propensity Score Overview: What do we use a propensity score for? How do we construct the propensity score? How do we implement propensity score es
More information1/24/15. In pursuit of evidence- based prac8ce. Accessibility of Available Evidence. Today s Purpose BUT FIRST... Levels of Evidence (LOE)
Speeding Up the EBP Process: Using Evidence that is Appraised, Available, and Ready To Go In pursuit of evidence- based prac8ce Clinician s best judgment How do we gain access to available evidence? Cailee
More informationGenetic Tests and Genetic Counseling How to Analyze Your Own Genome
Genetic Tests and Genetic Counseling 02-223 How to Analyze Your Own Genome Genetic Tests for Huntington Disease Hun7ngton Disease Incurable brain disorder that runs in families Movement, cogni7ve, and
More informationPosi%ve Psychotherapy for Youth at Clinical High- Risk for Psychosis
Posi%ve Psychotherapy for Youth at Clinical High- Risk for Psychosis Lauren Drvaric, MSc. Psych., PhD. Candidate (co- inves%gator) Doctoral Research Trainee, Complex Mental Illness, Centre for Addic%on
More informationFindings from the At Home / Chez Soi Demonstration Project in Canada. Paula Goering and Catharine Hume May 2, 2013
Findings from the At Home / Chez Soi Demonstration Project in Canada Paula Goering and Catharine Hume May 2, 2013 Outline for today Overview of Project Design Na8onal level findings re one year outcomes
More informationA review of approaches to identifying patient phenotype cohorts using electronic health records
A review of approaches to identifying patient phenotype cohorts using electronic health records Shivade, Raghavan, Fosler-Lussier, Embi, Elhadad, Johnson, Lai Chaitanya Shivade JAMIA Journal Club March
More informationStacie Fruth, PT, DHSc, OCS Michael Brickens, PT Tim Ellender, MD Jenny Gojmerac- Owens, NP Julie Welch, MD. Stacie Fruth, PT, DHSc, OCS
Physical Therapists on the Emergency Department Team: PT and MD Perspec8ves Stacie Fruth, PT, DHSc, OCS Michael Brickens, PT Tim Ellender, MD Jenny Gojmerac- Owens, NP Julie Welch, MD Combined Sec,ons
More informationTHE RARE DISEASES CLINICAL RESEARCH NETWORK AS A NESTED CULTURAL COMMONS
THE RARE DISEASES CLINICAL RESEARCH NETWORK AS A NESTED CULTURAL COMMONS Bre5 Frischmann, Benjamin N. Cardozo School of Law Katherine J. Strandburg, NYU School of Law Can Cui, NYU School of Law Case study
More informationEngage and Empower Pa.ents with Interac.ve Technology. Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012
Engage and Empower Pa.ents with Interac.ve Technology Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012 NAHAM - Pa.ent Access Services 2 Pa%ent Access Services
More informationHealth Informa.cs. Lecture 7. Samantha Kleinberg
Health Informa.cs Lecture 7 Samantha Kleinberg samantha.kleinberg@stevens.edu Prac.cali.es: preserving privacy Good prac.ces for preserving privacy Physical security Locked cabinet/office, don t print
More informationApplica(on of Causal Inference Methods to Improve Treatment of HIV in Resource Limited Se?ngs
Applica(on of Causal Inference Methods to Improve Treatment of HIV in Resource Limited Se?ngs Maya Petersen works.bepress.com/maya_petersen Divisions of Biosta,s,cs and Epidemiology, University of California,
More informationINNOVCare - Innovave Paent-Centred Approach for Social Care Provision to Complex Condions Methodology Report
WP7: METHODOLOGY REPORT The effects of a case management approach on the quality of life of rare disease paents in Salaj, Romania: a randomised control trial of efficacy Juliet Tschank, Katharina Handler
More informationDepartment of Emergency Office of Research. Shannon McNabb, MA, MPH Clinical Research Manager January 2017
Department of Emergency Medicine Office of Research Shannon McNabb, MA, MPH Clinical Research Manager January 2017 EM Study Tracking System UPDATED ON: 12/5/2016 TOTAL 68 Grants Submitted, Award Pending
More informationPlace of surgery in diagnos1c and therapeu1c strategies: New challenges
Place of surgery in diagnos1c and therapeu1c strategies: New challenges Philippe Métellus M.D., Ph.D. Department of Neurosurgery, CHU Timone, Marseille, France Place of surgery in diagnos1c and therapeu1c
More informationWHO posi)on paper on influenza vaccines*
WHO posi)on paper on influenza vaccines* Geneva, Switzerland Published in the Weekly Epidemiological Record on 23 November 2012 * This posi(on paper is concerned mainly with vaccines and vaccina(on against
More informationDebate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza Aeron Hurt WHO Collabora@ng Centre for Reference and Research on Influenza, Melbourne, Australia www.influenzacentre.org NA inhibitor
More informationCOMPARING MULTIPLE INTERVENTIONS WORKSHOP 1
COMPARING MULTIPLE INTERVENTIONS WORKSHOP 1 Lorne Becker, Tianjing Li, Chris Schmid 20 th Cochrane Colloquium Auckland, New Zealand October 1, 2012 1 Disclosures u Some of the work is funded by the Cochrane
More informationShould Me*ormin be contraindicated in pa4ents with CKD? TAYLOR MCBRIDE UNIVERSITY OF TEXAS/HEB PGY-1 COMMUNITY PHARMACY RESIDENT
Should Me*ormin be contraindicated in pa4ents with CKD? TAYLOR MCBRIDE UNIVERSITY OF TEXAS/HEB 2018-2019 PGY-1 COMMUNITY PHARMACY RESIDENT 1 Objec4ves Understand the changes to Me*ormin labeled use in
More informationLeveraging the HSX Clinical Data Repository to Improve Behavioral Health Care:
Leveraging the HSX Clinical Data Repository to Improve Behavioral Health Care: Insights from the Montgomery County Hospital Partnership HEALTHSHARE EXCHANGE BOARD OF TRUSTEES ANNUAL MEETING NOVEMBER 14,
More informationThe Availability of Homeopathic Medicinal Products (HMPs) in Europe with reference to the Matrix Report
The Availability of Homeopathic Medicinal Products (HMPs) in Europe with reference to the Matrix Report A presenta@on to the European Parliament CAM Interest Group 1 July 2015 By Stephen Gordon General
More informationCausal Inference from Complex Observa4onal Data. Samantha Kleinberg
Causal Inference from Complex Observa4onal Data Samantha Kleinberg samantha.kleinberg@stevens.edu Three key points We need causal knowledge Causes are hard to find It s not hopeless! Most striking, society
More informationRecording ac0vity in intact human brain. Recording ac0vity in intact human brain
Recording ac0vity in intact human brain Recording ac0vity in intact human brain BIONB 4910 April 8, 2014 BIONB 4910 April 8, 2014 Objec0ves: - - review available recording methods EEG and MEG single unit
More informationWell Differen*ated Thyroid Microcarcinoma. Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel School of Medicine at Dartmouth
Well Differen*ated Thyroid Microcarcinoma Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel School of Medicine at Dartmouth Objec*ves (1) Review epidemiology of thyroid microcarcinoma.
More informationRight Answers, Wrong Ques2ons. Ralph I Horwitz
Right Answers, Wrong Ques2ons Ralph I Horwitz Disclosures Employed by GlaxoSmithKline Views expressed reflect mine alone and not those of GSK Right Answer, Wrong Ques2on A young couple moves into an apartment
More informationRecrea&onal Therapy. Thomas K. Skalko, Ph.D., LRT/CTRS Chair, Commi<ee on Accredita&on of Recrea&onal Therapy Educa&on
Recrea&onal Therapy Thomas K. Skalko, Ph.D., LRT/CTRS Chair, Commi
More informationTime is Muscle. In this talk, I will address 3 ques7ons: School of Rehabilita?on Science Reaching Further
School of Rehabilita?on Science Reaching Further Time is Muscle Michelle Kho, PT, PhD Canada Research Chair in Cri?cal Care Rehabilita?on and Knowledge Transla?on McMaster University, Hamilton, ON Clinician
More informationPEDIATRIC CT SCAN WHERE ARE WE, DO WE REALLY KNOW THE RISKS AND WHICH WAY TO FOLLOW?
PEDIATRIC CT SCAN WHERE ARE WE, DO WE REALLY KNOW THE RISKS AND WHICH WAY TO FOLLOW? Carla Conceição, MD Neuroradiology Department Hospital D. Estefânia, CHLC Hospital da Luz PEDIATRIC CT SCAN WHERE ARE
More informationResolving the PSA testing controversy. Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg
Resolving the PSA testing controversy Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg Professor Villis Marshall AC Introduc)on Guidelines aim to inform tes)ng for the
More informationPropensity Score Methods for Longitudinal Data Analyses: General background, ra>onale and illustra>ons*
Propensity Score Methods for Longitudinal Data Analyses: General background, ra>onale and illustra>ons* Bob Pruzek, University at Albany SUNY Summary Propensity Score Analysis (PSA) was introduced by Rosenbaum
More informationTargeted Treatments for Au0sm: from Genes to Pharmacology
Targeted Treatments for Au0sm: from Genes to Pharmacology Paul Wang, MD Associate Clinical Professor of Pediatrics, Yale University School of Medicine Vice President for Clinical Development, Seaside Therapeu0cs,
More informationIdentifying Engineering, Clinical and Patient's Metrics for Evaluating and Quantifying Performance of Brain- Machine Interface Systems
Identifying Engineering, Clinical and Patient's Metrics for Evaluating and Quantifying Performance of Brain- Machine Interface Systems Jose Pepe L. Contreras-Vidal, Ph.D. Department of Electrical & Computer
More informationForward Looking Statements
March 12, 2015 1 Forward Looking Statements This presenta5on contains forward- looking statements within the meaning of the Private Securi5es Li5ga5on Reform Act of 1995 that involve substan5al risks and
More informationResearch Update: Effects of Alterna5ves to Tradi5onal Fungicide and Winter Fer5liza5on Prac5ces on Microdochium Patch
Research Update: Effects of Alterna5ves to Tradi5onal Fungicide and Winter Fer5liza5on Prac5ces on Microdochium Patch Clint Ma)ox, Alec Kowalewski, and Brian McDonald Department of Hor
More informationTopic 1: What Are Embedded Pragmatic Clinical Trials?
Topic 1: What Are Embedded Pragmatic Clinical Trials? Part 1: Lesley Curtis, PhD Director, Center for Pragmatic Health Systems Research Duke Clinical Research Institute Collaboratory epct Training Workshop
More informationConflicts of interest. Objec5ves / Outline. Pulmonary rehabilita5on. Pulmonary rehabilita5on in COPD. Pulmonary rehabilita5on in COPD 11/26/13
Conflicts of interest UBC I have no conflicts of interest related to this presenta5on Treatment op+ons From a global perspec+ve: Non- pharmaceu+cal treatments Pulmonary Fibrosis Founda5on Summit La Jolla,
More informationFor more information about how to cite these materials visit
Author(s): Rajesh Mangrulkar, M.D., 2013 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Non-commercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationToday. HW6 ques.ons? Next reading presenta.on: Friday (R25) Sta.s.cal methods
Today HW6 ques.ons? Next reading presenta.on: Friday (R25) Sta.s.cal methods Inferen.al sta.s.cs Inferen.al sta.s.cs: Sta.s.cal tests you apply to quan.ta.ve data to determine the likelihood that the results
More informationCausal Inference: predic1on, explana1on, and interven1on
Causal Inference: predic1on, explana1on, and interven1on Lecture : Mechanisms, Interven1ons, and Randomized Controlled Trials Samantha Kleinberg samantha.kleinberg@stevens.edu Blame Who s at fault for
More informationASSET- BASED COMMUNITY DEVELOPMENT & SBCB: THEORY
Short Guide to ABCD - The art of asking the right questions ASSET- BASED COMMUNITY DEVELOPMENT & SBCB: THEORY DEFICIT- BASED ASSET- BASED Problems Possibili9es Blame Shared ownership What s missing What
More informationIMPROVING GLOBAL ESTIMATES: PROCESS AND MILESTONES IATT Webinar June 7 th 2016
Where did we start? Where did we get to? Where do we want to go? IMPROVING GLOBAL ESTIMATES: PROCESS AND MILESTONES IATT Webinar June 7 th 2016 Mar6na Penazzato Paediatric advisor HIV Department WHO, Geneva-
More informationWhat Happened in the IN.PACT Deep Trial. Zaheed Tai, DO,FACC,FSCAI Bos4ck Heart Center Winter Haven, FL
What Happened in the IN.PACT Deep Trial Zaheed Tai, DO,FACC,FSCAI Bos4ck Heart Center Winter Haven, FL BTK Revasculariza>on Challenges Long, complex, ocen calcified nature of lesions 1 OCen associated
More informationInsights from CISCRP s 2017 Percep9ons & Insights Study March 2018
Insights from CISCRP s 2017 Percep9ons & Insights Study March 2018 Summary Overall public and patient attitudes, perceptions and experiences consistent with past studies Probing to identify underlying
More information2018 Conference on Ending Homelessness. Informa(onal Session Proposal Webinar
2018 Conference on Ending Homelessness Informa(onal Session Proposal Webinar Welcome To The Webinar Thank you for joining today s webinar! All par:cipants will be muted during the webinar to ensure good
More informationTraining + U*lizing Student Staff as Ac*ve Bystanders
Training + U*lizing Student Staff as Ac*ve Bystanders Ka*e Sorokas Kent State University ksorokas@kent.edu Jennifer O Connell Kent State University joconne5@kent.edu Outline Descrip*on of Kent State University
More informationThe future of ARIA guidelines
The future of ARIA guidelines Evidence- based medicine GRADE Recommenda
More informationOhio Medical Marijuana Control Program
Ohio Medical Marijuana Control Program Guiding Principles Ohio Medical Marijuana Control Program is: 1. Pa;ent-centered and safe 2. Responsive, data-driven, and transparent 3. Flexible, scalable, and sustainable
More informationNutri&on And Diete&c Services in The Context to Chronic Kidney Disease (CKD) And The Need of Diasporic Engagement
Nutri&on And Diete&c Services in The Context to Chronic Kidney Disease (CKD) And The Need of Diasporic Engagement Dr. Nahlaa Khalifa Clinical Nutri,on Department, Faculty of Applied Medical Sciences, King
More informationAggressive Medical Management with or without Angioplasty and Sten8ng for Symptoma8c Intracranial Atherosclero8c Stenosis: Long Term Results
Aggressive Medical Management with or without Angioplasty and Sten8ng for Symptoma8c Intracranial Atherosclero8c Stenosis: Long Term Results Disclosures Funding by NINDS U01 NS058728 Boston Scien8fic provided
More informationPsychosocial Aspects of Cervical Screening. Dr WH Li 24 May 2014
Psychosocial Aspects of Cervical Screening Dr WH Li 24 May 2014 Cervical Screening Cervical cytology screening highly effec@ve in detec@ng premalignant condi@ons Drama@cally decrease incidence and mortality
More informationMetabolically Healthy Obese:
Metabolically Healthy Obese: Reality or Fantasy? Mercedes Carnethon, Ph.D., FAHA Associate Professor, Department of Preven:ve Medicine Feinberg School of Medicine at Northwestern University May 15, 2014
More informationMedica8on Assisted Treatment (MAT) in Jails and Community- Based SeDngs
Medica8on Assisted Treatment (MAT) in Jails and Community- Based SeDngs Lisa Ramirez, Lead Program Specialist, Texas Department of State Health Services, Mental Health and Substance Abuse Division Rebecca
More informationPaget s Disease of Bone
Paget s Disease of Bone Copyright Copyright 2019 American 2019 American Associa7on Associa7on of Clinical of Clinical Endocrinologists Endocrinologists 1 A Common Bone Disorder Paget s disease of bone
More informationRecent Clinical Trials in CCTA Implica3ons for Prac3ce
Recent Clinical Trials in CCTA Implica3ons for Prac3ce Tej Sheth Associate Professor of Medicine McMaster University Interven3onal Cardiologist Hamilton Health Sciences and Niagara Health System 65 F,
More informationProcess of Science and hypothesis tes2ng in Behavioral Ecology
Process of Science and hypothesis tes2ng in Behavioral Ecology Goal: understand the way that scien2fic hypotheses and methodologies are used to gain knowledge. What separates science from non- science?
More informationQuan%ta%ve Tools for Benefit/Risk Op%miza%on in Medical Imaging MIRD CommiAee Pamphlet
Quan%ta%ve Tools for Benefit/Risk Op%miza%on in Medical Imaging MIRD CommiAee Pamphlet Wesley Bolch, PhD, PE, DABHP, FHPS, FAAPM Medical Physics Program Department of Biomedical Engineering University
More informationPATRICK ANSAH PRINCIPAL INVESTIGATOR 22/02/2016
Evaluation of the Men A specific antibody persistence in Ghanaian children more than five years after immunization with PsA-TT (2.5 μg, 5 μg, or 10 μg polysaccharide concentration) PATRICK ANSAH PRINCIPAL
More informationEpidemiology is: The scien)fic study of disease distribu)on and the factors that cause diseases to spread in communi)es
Speak Epidemiology Epidemiology is: The scien)fic study of disease distribu)on and the factors that cause diseases to spread in communi)es Effec3ve research advocates Analyze the facts Educate others Build
More informationIn this module we will cover Correla4on and Validity.
In this module we will cover Correla4on and Validity. A correla4on coefficient is a sta4s4c that is o:en used as an es4mate of measurement, such as validity and reliability. You will learn the strength
More informationResults Members Survey 2012
Results Members Survey 2012 Phil Sell October, 2012 Members Survey 2012 Survey open September 26 th to October 7 th Separate survey for non member conference par:cipants 199 members ( sample size 563)
More informationMul$ple Risk Factor Interven$on Trial (MRFIT) in Osteoarthri$s
Mul$ple Risk Factor Interven$on Trial (MRFIT) in Osteoarthri$s Marc C. Hochberg, MD, MPH Professor of Medicine and Epidemiology and Public Health Relevant Disclosures I have received consul$ng and speaking
More information1. ATHENA Network, AVAC, and Salamander Trust with UN Women, undertook this mul>-stage review of the global status of access to an>retroviral therapy
1. ATHENA Network, AVAC, and Salamander Trust with UN Women, undertook this mul>-stage review of the global status of access to an>retroviral therapy (ART) for women living with HIV 2. This is the first
More informationThe design of the PRaCTICED trial: Decisions, decisions, decisions
The design of the PRaCTICED trial: Decisions, decisions, decisions Michael Barkham Centre for Psychological Services Research University of Sheffield Metanoia: September 2013 Acknowledgements BACP Research
More informationConsidera*ons when undergoing personal genotyping
Considera*ons when undergoing personal genotyping Kelly Ormond, MS, CGC Louanne Hudgins, MD, FACMG January 19, 2011 GENE 210 Disclosures and introduc*ons Professor Ormond provided paid consulta*on for
More informationEffec&ve Messaging for Suicide Preven&on:
Effec&ve Messaging for Suicide Preven&on: Anara Guard anara@suicideispreventable.org Lessons from a statewide campaign and from a na&onal framework This morning The Know the Signs statewide social marke&ng
More informationIn 2012, the HEARTH Act consolidated the three types of funding ac=vi=es in the McKinney Act (Suppor=ve Housing SHP, Shelter Plus Care and Sec=on 8
In 2012, the HEARTH Act consolidated the three types of funding ac=vi=es in the McKinney Act (Suppor=ve Housing SHP, Shelter Plus Care and Sec=on 8 Moderate Rehab SRO Program) and created one single program
More informationAssessment of locomo,on ability
Université catholique de Louvain Cliniques universitaires St-Luc Département de Médicine Physique et de Réadapta,on Introduc,on Assessment of locomo,on ability Development of ABILOCO - ABILOCO-Kids Caty
More informationNocturia - a Significant Symptom of Mul8factorial Nature. Objec8ves of the Talk. Dr. Boris Friedman May 25, 2011
Nocturia - a Significant Symptom of Mul8factorial Nature Dr. Boris Friedman May 25, 2011 Objec8ves of the Talk 1. Review the characteriza8on of nocturia and implica8ons on morbidity and mortality 2. Review
More informationDesigning and Delivering ACT Interven2ons for Individuals with Medical Condi2ons:
ACBS Symposium World Con 12 Designing and Delivering ACT Interven2ons for Individuals with Medical Condi2ons: Transdiagnos2c principles and key change processes Megan Oser, PhD Vanessa Alvarez, MA Gabe
More informationMalnutri)on Universal Screening Tool (MUST)
Malnutri)on Universal Screening Tool () Nutri&on screening mandated in acute care se1ngs in the US, UK and Canada - Iden&fy malnourished pa&ents and those at risk à warrant more detailed assessment/treatment
More informationC-reac've protein-based TB screening
C-reac've protein-based TB screening Advanced TB Diagnos0cs Workshop June 22, 2017 Chris0na Yoon, MD, MPH University of California, San Francisco Systema'c TB screening Recommendations 1-3 Should be done:
More informationEthical Guidelines 9/24/15. Controlled Substance Update Texas Nurse Prac66oners Annual Conference Objec6ves
Texas Nurse Prac66oners Annual Conference 2015 Kimberly H. Oas, MSN, APRN, FNP- BC Jan Zdanuk, DNP, APRN, FNP- BC, FAANP Ethical Guidelines Speakers report no rela6onships with business or industry that
More informationGestalt of Fatigue Risk Management within a Safety Management System
Gestalt of Fatigue Risk Management within a Safety Management System Aircraft Inspection & Maintenance Seminar Coogee Bay October 24, 2017 Robert ForsterLee Fatigue Enablers What is Gestalt? Gestalt is
More informationWelcome to Pa+ent Safety in Epilepsy Monitoring Units. Cosponsored by the American Epilepsy Society and the Na7onal Associa7on of Epilepsy Centers
Welcome to Pa+ent Safety in Epilepsy Monitoring Units Cosponsored by the American Epilepsy Society and the Na7onal Associa7on of Epilepsy Centers Overview of Educa+onal Program Web- based program designed
More informationFalls in older patients with cancer: Impact on treatment, fall assessment and reporting
Falls in older patients with cancer: Impact on treatment, fall assessment and reporting Schroder Sa*ar 1, Shabbir Alibhai 2, Sandra Spoelstra 3, Mar8ne MTE Puts 1 1 Lawrence S. Bloomberg Faculty of Nursing,
More informationA Transla)onal Framework for Methodological Rigor to Improve Pa)ent Centered Outcomes in End of Life Cancer Research
A Transla)onal Framework for Methodological Rigor to Improve Pa)ent Centered Outcomes in End of Life Cancer Research Francesca Dominici, PhD Senior Associate Dean for Research Professor of Biostatistics
More information